Rosiglitazone, (HPLC), >=98% (HPLC)

Rosiglitazone, (HPLC), >=98% (HPLC)

Application

Rosiglitazone has been used:as a medium constituent for adipocyte differentiationin the cell proliferation assay in human colonic carcinoma cell linesfor Bcl-2-like protein 13 (Bcl2l13) expression in adipocytesas a peroxisome proliferator-activated receptor gamma (PPAR?) ligand

Biochem/physiol Actions

Rosiglitazone is a potent agonist for PPARγ with an EC50 of 43 nM for the human receptor. It is antidiabetic, working as an insulin sensitizer by binding to the PPARγ receptors in fat cells and making the cells more responsive to insulin.

Features and Benefits

This compound is a featured product for ADME Tox and Gene Regulation research. Discover more featured ADME Tox and Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the AMPKs and Nuclear Receptors (PPARs) pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

10, 50 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573875 Rosiglitazone, (HPLC), >=98% (HPLC) 100 YASAKCUCGLMORW-UHFFFAOYSA-N 1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23) SIGMA-ALDRICH
£125.78 (exc VAT) per 10MG
-
+
3573876 Rosiglitazone, (HPLC), >=98% (HPLC) 100 YASAKCUCGLMORW-UHFFFAOYSA-N 1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23) SIGMA-ALDRICH
£454.07 (exc VAT) per 50MG
-
+